Alliance for Pandemic Preparedness
April 7, 2021
Anti-SARS-CoV-2 RBD IgG Responses in Convalescent versus Naïve BNT162b2 Vaccine Recipients
Category: Article Summary
Topic: Vaccines and Immunity
Keywords (Tags): vaccine
- IgG responses measured 14 days after the first and second dose of the Pfizer-BioNTech vaccine among convalescent individuals (n = 12) and age- and sex-matched individuals with no prior infection (n = 54) showed that convalescent individuals showed higher absolute anti-S1/S2 IgG levels (220 ± 42 vs. 37 ± 3 AU/ml) compared to naïve vaccinees at 14 days after the first dose. IgG levels of convalescent individuals 14 days after the first dose were similar to those of individuals without prior infection after the second dose. 2% of naïve vaccine recipients and 75% of convalescent individuals showed IgG levels higher than 80 AU/ml after the first dose of vaccine, which the authors note has been shown to predict neutralizing antibody titers.
Azzi et al. (Mar 2021). Anti-SARS-CoV-2 RBD IgG Responses in Convalescent versus Naïve BNT162b2 Vaccine Recipients. Vaccine. https://doi.org/10.1016/j.vaccine.2021.03.086